Conference participants have concluded that policy reforms are needed to strengthen healthcare systems in Europe through off-patent medicines, and consider that the EU needs to encourage the use of generic, biosimilar and value-added medicines to increase access of patients to medicines and guarantee budgetary sustainability.
The deputy director of BioSim, Isabel del Río, participated in the conference exposing the situation of biosimilar medicines in the Spanish National Health System.
